Experience
Sandoz Inc.
AbbVie Biotechnology, Ltd
A biosimilar drug manufacturer filed inter partes review (IPR) petitions challenging two patents held by Finnegan client AbbVie Biotechnology Ltd, which cover methods of treating Crohn’s disease and ulcerative colitis using Humira®. The Patent Trial and Appeal Board (PTAB) issued two decisions, each denying institution on all grounds and holding that the petitioner failed to establish a reasonable likelihood that any of the challenged claims were unpatentable.
Sandoz Inc. v. AbbVie Biotechnology, Ltd, IPR2018-01987, -01988, PTAB, Judges Ankenbrand, Harlow, Mitchell
Carnegie Institution of Washington et al. v. Pure Grown Diamonds, Inc. et al.
Pure Grown Diamonds, Inc. et al.
Finnegan secures jury verdict of willful infringement for ProSlide
ProSlide Technology, Inc.
Bright Data Ltd. v. NetNut Ltd.
NetNut Ltd.
Delta Faucet Company v. Globe Union Industrial Corp. et al.
Globe Union Industrial Corp.
Hawk Technology Systems, LLC v. Kirkland's Inc.
Kirkland's Inc.
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Rondevoo Technologies, LLC v. RSIP Vision, Inc.
RSIP Vision, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.